Invikafusp alfa, a dual T-cell agonist targeting subsets of tumor-infiltrating lymphocytes, can elicit responses in patients with heavily pretreated gastrointestinal cancers, according to research ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Zegfrovy (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC ...

The FDA approved Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

Ashwin Kishtagari, MD, of Vanderbilt University Medical Center in Nashville, summarizes 7 studies presented at the EHA 2025 Congress.

Adding atezolizumab and bevacizumab to TACE can improve outcomes in previously untreated, unresectable HCC, data suggest.

Provisions in the new tax and spending bill passed by the Senate would go even further than the House bill in removing health ...

Breast cancer patients may have inferior recurrence-free survival after neoadjuvant chemotherapy if they are overweight or obese at diagnosis.

Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

Uterine cancer cases and deaths are projected to increase in Black women and White women in the United States.

Breast cancer survivors have a lower risk of Alzheimer's disease than cancer-free control individuals, data suggest.

Under the “One Big Beautiful Bill Act," 10.9 million Americans would lose health insurance by 2034, according to estimates by the Congressional Budget Office.

President Donald Trump’s “One Big Beautiful Bill” cuts federal spending on Medicaid and Affordable Care Act marketplaces by about $1 trillion over a decade, according to the nonpartisan Congressional ...